Physician profile
Paul P Doghramji
NPI 1417937715
$617,254.07
in general payments reported to CMS, 2019-2025
98 companies · $162K in 2025
The $162K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $46K · 2020: $71K · 2021: $55K · 2022: $48K · 2023: $107K · 2024: $129K · 2025: $162K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $146K · Consulting Fee: $129K · Travel and Lodging: $53K · Honoraria: $47K · Food and Beverage: $21K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,575 · Education: $277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $146,291.46 |
| Consulting Fee | $128,922.75 |
| Travel and Lodging | $53,492.52 |
| Honoraria | $46,750.00 |
| Food and Beverage | $20,772.36 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,575.00 |
| Education | $277.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $107,398.33 | 2022-2025 | Auvelity, Sunosi, Symbravo |
| Eisai INC. | $86,061.74 | 2019-2022 | |
| Amgen INC. | $57,433.30 | 2019-2025 | Repatha, Repatha, Krystexxa |
| Idorsia Pharmaceuticals US INC | $53,783.53 | 2022-2024 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39,117.39 | 2022-2025 | Caplyta |
| Jazz Pharmaceuticals INC. | $34,865.41 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $32,516.28 | 2019-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Allergan, INC. | $27,297.70 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $27,166.91 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $25,348.78 | 2019-2025 | Vraylar, Qulipta, Synthroid |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21,837.18 | 2024-2025 | Rejoyn, Rexulti |
| Novo Nordisk INC | $20,781.47 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $17,201.92 | 2019-2025 | |
| Janssen Global Services, LLC | $8,592.83 | 2024-2025 | Spravato |
| Tonix Medicines, INC. | $8,132.09 | 2025 | Tonmya |
Show all 97 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $6,875.00 | 2021 | |
| Lilly USA, LLC | $6,002.61 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Biogen, INC. | $4,922.00 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $3,702.80 | 2019-2023 | Belsomra, Steglatro, Vaxneuvance |
| Bayer Healthcare Pharmaceuticals INC. | $2,847.02 | 2020-2025 | |
| Neurocrine Biosciences, INC. | $2,686.88 | 2020-2024 | Ingrezza |
| Harmony Biosciences LLC | $2,347.09 | 2020-2025 | Wakix |
| Sobi, INC | $2,217.99 | 2025 | |
| Regeneron Pharmaceuticals, INC. | $2,160.00 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $1,475.45 | 2021 | |
| Janssen Scientific Affairs, LLC | $1,450.00 | 2024 | |
| Glaxosmithkline, LLC. | $1,094.23 | 2019-2025 | Trelegy Ellipta, Shingrix, Benlysta |
| Daiichi Sankyo INC. | $1,088.56 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,078.45 | 2019-2025 | Xifaxan, Relistor |
| Paratek Pharmaceuticals, INC. | $902.63 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $775.36 | 2024-2025 | Voquezna |
| Corcept Therapeutics | $576.87 | 2023-2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $494.00 | 2019-2025 | |
| Gilead Sciences, INC. | $397.43 | 2020-2025 | |
| Amarin Pharma, INC. | $381.16 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $377.32 | 2019-2024 | Trintellix |
| Sanofi-Aventis U.S. LLC | $363.99 | 2019-2023 | |
| Abbott Laboratories | $355.89 | 2021-2025 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $350.88 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $347.01 | 2019-2025 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $334.98 | 2019-2025 | Jardiance |
| Lundbeck LLC | $326.35 | 2020-2025 | Rexulti, Vyepti |
| Astellas Pharma US INC | $324.75 | 2019-2025 | Veozah |
| Kowa Pharmaceuticals America, INC. | $289.69 | 2020-2025 | Zoryve |
| Exact Sciences Corporation | $271.33 | 2023-2025 | Cologuard Collection Kit |
| Upsher-Smith Laboratories LLC | $197.46 | 2019-2023 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $170.60 | 2022 | |
| Corium, LLC | $163.10 | 2022-2023 | Azstarys |
| Antares Pharma, INC. | $157.52 | 2021-2025 | Xyosted |
| Supernus Pharmaceuticals, INC. | $139.79 | 2019-2023 | Tlando, Xyosted, Qelbree |
| Bausch Health US, LLC | $137.87 | 2019-2021 | |
| Tolmar, INC. | $132.57 | 2023-2025 | Jatenzo |
| Mannkind Corporation | $107.94 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $93.11 | 2024-2025 | Fanapt |
| Ironshore Pharmaceuticals INC. | $89.27 | 2019-2024 | Jornay Pm |
| Impel Pharmaceuticals INC. | $86.75 | 2022-2023 | Trudhesa |
| Dexcom, INC. | $84.43 | 2023-2025 | Dexcom G6 Transmitter |
| Genentech USA, INC. | $72.16 | 2020-2021 | |
| Horizon Therapeutics Plc | $68.95 | 2020-2021 | |
| Esperion Therapeutics, INC. | $68.25 | 2025 | Nexletol |
| Boston Scientific Corporation | $65.61 | 2022-2024 | Bodyguardian |
| Currax Pharmaceuticals LLC | $62.97 | 2020-2022 | |
| Adlon Therapeutics L.P. | $57.35 | 2019-2021 | |
| Shire North American Group INC | $46.77 | 2019 | |
| Mayne Pharma Commercial LLC | $43.34 | 2023 | |
| Biodelivery Sciences International, INC. | $43.20 | 2020-2021 | |
| Halozyme INC | $42.44 | 2023 | |
| Inspire Medical Systems, INC. | $38.46 | 2024 | Inspire |
| Aytu Biopharma, INC. | $38.38 | 2019 | |
| Acerus Pharmaceuticals Corporation | $37.37 | 2021 | |
| Dermira, INC. | $36.97 | 2020 | |
| Redhill Biopharma INC. | $36.66 | 2024 | Talicia |
| Azurity Pharmaceuticals, INC. | $36.12 | 2024 | Horizant |
| Ardelyx, INC. | $32.89 | 2024 | Ibsrela |
| Sanofi Pasteur INC. | $30.65 | 2019 | |
| Endo Pharmaceuticals INC. | $30.41 | 2019-2021 | |
| Seqirus USA INC | $29.97 | 2024 | Flucelvax, Fluad |
| Avanir Pharmaceuticals, INC. | $29.86 | 2019-2022 | |
| Braeburn INC. | $28.09 | 2025 | Brixadi |
| Sumitomo Pharma America, INC. | $27.14 | 2025 | Gemtesa |
| Intra-Sana Laboratories | $25.06 | 2022-2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Vivus LLC | $24.07 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $23.63 | 2019 | |
| Alkermes, INC. | $23.52 | 2021 | |
| Clarus Therapeutics INC. | $23.46 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $21.26 | 2025 | Eliquis |
| Avadel Cns Pharmaceuticals, LLC | $20.94 | 2024 | Lumryz |
| Kaleo, INC. | $20.21 | 2021 | |
| Ibsa Pharma INC. | $20.02 | 2025 | Flector, Licart, Tirosint |
| Vbi Vaccine (Delaware) INC. | $19.60 | 2022 | |
| Collegium Pharmaceutical, INC. | $19.52 | 2023 | Xtampza |
| Xeris Pharmaceuticals, INC. | $19.17 | 2025 | Recorlev |
| Mission Pharmacal Company | $18.35 | 2020 | |
| Hologic Sales and Service, LLC | $17.04 | 2025 | Aptima, Thinprep 2000 Processor |
| Intuity Medical INC | $13.92 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Dynavax Technologies Corporation | $13.91 | 2021 | |
| Philips North America LLC | $13.39 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$8,484.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Doghramji listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.